AI assistant
GlaxoSmithKline PLC — Director's Dealing 2016
Jul 18, 2016
5262_dirs_2016-07-18_206eb2be-b3b0-4ced-9bd3-8eb81f8c61b7.html
Director's Dealing
Open in viewerOpens in your device viewer
National Storage Mechanism | Additional information
You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.
RNS Number : 4890E
GlaxoSmithKline PLC
18 July 2016
GlaxoSmithKline plc (the 'Company')
Transaction notification
1.
Details of PDMR/person closely associated with them ('PCA')
a)
Name
Dr P J T Vallance
b)
Position/status
President, Pharmaceuticals R&D
c)
Initial notification/
amendment
Initial notification
2.
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)
Name
GlaxoSmithKline plc
b)
LEI
5493000HZTVUYLO1D793
3.
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted
a)
Description of the financial instrument
Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
b)
Nature of the transaction
Increase in notional interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 14 July 2016, on Ordinary Shares held in the Company's Deferred Investment Award Programme.
c)
Price(s) and
volume(s)
| Price(s) | Volume(s) |
| £16.4900 | 454.329 |
d)
Aggregated information
Aggregated volume Price
n/a (single transaction)
e)
Date of the transaction
2016-07-14
f)
Place of the transaction
n/a
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHXVLFFQDFEBBF
//<![CDATA[$.ajaxSetup({headers: {'__RequestVerificationToken':'tIcxDgIt-91PeGIrSmN3bE2rEVMNytXHqtwCBNa0v8Y0kjkf9WOfe4YF9nBEs598UMlJXpeSHmZUBAEJEZjxSWoXq_HZ_Jlmg_FgFS3h8Mw1:qDS_30PBJmxSp-1RiSyBCgK184f1Os2O2DZXQGmTx6MpZ3xEJMhCa1kIt55ulBKqnCy_AcKZvpnV_ELoP2qD2STfr9noR_cUFaRt2l3MxFs1'}});//]]>